Unknown PHASE4 INTERVENTIONAL 1-arm NCT04454151

Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis (FAP)

Sponsor: Tel Aviv University

Conditions Familial Adenomatous Polyposis

Updated 6 times since 2020 Last updated: Jun 30, 2020 Started: Aug 1, 2020 Primary completion: Jan 1, 2022 Completion: Apr 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Familial Adenomatous Polyposis and is currently ongoing. Tel Aviv University leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Aug 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tel Aviv University
Tel-Aviv Sourasky Medical Center

Data source: Tel-Aviv Sourasky Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tel Aviv, Israel